On November 8, 2024, Soligenix, Inc. (SNGX) announced financial results for the third quarter of 2024 and provided a business update. The company has multiple milestones coming up in the near future, including the initiation of the Phase 3 clinical trial of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL) before the end of 2024, the initiation of a Phase 2 trial of SGX945 in Behcet's disease with topline results expected in the first half of 2025, and topline results from the ongoing Phase 2 trial of SGX302 in mild-to-moderate psoriasis in the first half of 2025.
